Abstracts
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Thomson Reuters, Washington, DC, USA, 2 Thomson Reuters, Washington, DC, USA, 3 Boehringer-Ingelheim, Ridgefield, CT, USA OBJECTIVES: The goal of this study is to describe the timing of the Hypoactive Sexual Desire Disorder (HSDD) diagnosis with that of depression/anxiety in a subgroup of women suffering from both disorders and determine which diagnosis came firstdepression/anxiety or HSDD. In addition it describes the use of both antidepressants and anxiolytics in this subgroup. METHODS: Marketscan® Research Databases were used to identify women aged 18-64 with an ICD-9-CM coded diagnosis of HSDD (302.71) from January 1, 1998-December 31, 2007 who also had an ICD-9-CM coded diagnosis of depression or anxiety (293.84, 296.2x, 296.3x, 300.0x, 300.4, 309.1, 311, v79.0) . The first physician visit with an HSDD diagnosis was the index date. Antidepressant and anxiolytic use was examined in the 24-month study period (12-months before and following index). RESULTS: A total of 957 (24.1%) of 3,975 women identified with HSDD also had a diagnosis of anxiety or depression in the study period. In this group, 34.7% (n = 332) had a depression/anxiety-coded claim appear after their HSDD-coded claim (after cohort), conversely, 65.3% (n = 625) had a depression/anxiety-coded claim appear on or before their HSDD-coded claim (before cohort). The majority of women in both the after and before cohorts were prescribed an antidepressant or anxiolytic in the study period, 78.3% (n = 260) and 86.1% (n = 538) respectively. Sixty percent (n = 156) and sixty-five percent (n = 351) of these women went on to discontinue use of the same. CONCLUSIONS: Over 24% of women with HSDD also suffer with depression/anxiety. More than one-third of these women developed their depression/anxiety diagnosis after being diagnosed with HSDD. A larger proportion of women had a diagnosis of depression and/or anxiety on or before that of HSDD. This may be evidence that both depression/anxiety and HSDD often present in tandem and that doctors feel competent to make such diagnoses concurrently. Additionally, intervention with antidepressants or anxiolytics appear inadequate to treat this population.
PIH6 PREVALENCE AND PREDICTORS OF POLYPHARMACY AMONGST ELDERLY PATIENTS: A POPULATION-BASED COHORT STUDY
Slabaugh SL 1 , Maio V 1 , Abouzaid S 2 , Templin M 1 1 Thomas Jefferson University, Philadelphia, PA, USA, 2 Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA OBJECTIVES: We sought to evaluate the prevalence of polypharmacy, and to determine patient characteristics that are predictive of exposure to polypharmacy in the elderly population of Emilia-Romagna, Italy. METHODS: We conducted a retrospective cohort study of the 2007 Emilia-Romagna outpatient pharmacy database linked with patient information available from a demographic file of approximately 1 million Emilia-Romagna residents aged ≥65 years. The cohort was comprised of 887,165 elderly patients who had at least one prescription filled during the study year. Using the World Health Organization's Defined Daily Dose (DDD) to determine the duration of treatment for a given drug, we defined a polypharmacy episode as overlapping treatment with 5 or more medications occurring for at least one day. The prevalence of polypharmacy was measured together with patient characteristics found to be predictive of polypharmacy exposure. RESULTS: A total of 349,689 elderly in the population (39.4%) were exposed to at least one episode of polypharmacy. The prevalence of polypharmacy substantially increased with age, (32.7% for those ages 65-74, over 45% for those ages 75+). Over 35% of those exposed to polypharmacy were exposed for 101 or more days of the year. The top three classes of medications involved in polypharmacy were antithrombotics, peptic ulcer disease and gastroesophageal reflux disease agents, and angiotensin-converting enzyme inhibitors. Compared to unexposed subjects, elderly exposed to polypharmacy were older, were more likely to be male, and had a greater number of chronic conditions. CONCLUSIONS: This study provides evidence that the prevalence of polypharmacy in the elderly in Emilia-Romagna is substantial. Educational programs targeting primary care physicians should be developed to make them aware of the magnitude of polypharmacy phenomenon, as well of patient characteristics associated with polypharmacy to ensuring safe, effective, and appropriate use of medication in the elderly population. Non-medical use of prescription drugs (NMPUD) is a serious problem in the US. This problem is even more concerning among pregnant women since nonmedical use of prescription drugs has the potential to harm both mother and fetus. However, our knowledge about the prevalence of NMPUD among pregnant women and its predictors is limited. This study attempted to fill these gaps. Objectives of this study were: 1) To estimate the prevalence of NMUPD among pregnant women, and 2) To determine various predictors of NMUPD among pregnant women. METHODS: This study used data from 2007 National Survey on Drug Use and Health (NSDUH). Sample consisted of non-institutionalized, pregnant women who were 12 years or older. Multiple logistic regression analyses which adjusted for the complex survey design were conducted to estimate the relationship between NMUPD among pregnant women and demographic characteristics. RESULTS: The sample consisted of 956 respondents out of which 92 (9.62%) had engaged in NMUPD in the past year. Among different categories of prescription drugs, prevalence of non-medical use was highest for pain relievers (5.27%), followed by tranquilizers (1.65%), stimulants (1.93%), and sedatives (0.51%). Results from the logistic regression showed significant relationships between past year NMUPD and poor health status (O.R. = 5.28, 95% CI: 1.37-20.28), past year use of tobacco (O.R. = 2.28, 95% CI: 1.003-5.226), and African American race (O.R. = 0.19, 95% CI: 0.06-0.52) or other nonwhite races (O.R. = 0.08, 95% CI: 0.02-0.29) at α = 0.05. CONCLUSIONS: Pain relievers are used most frequently non-medically by pregnant women when compared to the other prescription drugs. Pregnant women, who are white, have poorer health and those who smoke are more likely to engage in NMUPD than the others. This study highlights the group of pregnant women that are more vulnerable to NMUPD. Physician need to be careful while prescribing medication to these high risk groups.
PIH7 PREDICTORS OF NON-MEDICAL USE OF PRESCRIPTION DRUGS AMONG PREGNANT WOMEN IN THE UNITED STATES

PIH8 DOES TRIAL PARTICIPATION IMPACT ON THE PSYCHOMETRIC PROPERTIES OF SELF-REPORT DEPRESSION IN POSTNATAL WOMEN?
Rankin J 1 , Martin CR 2 1 University of the West of Scotland, Paisley, UK, 2 University of the West of Scotland, Ayr, UK OBJECTIVES: It is assumed within the context of clinical trials that the measurement characteristics of self-report outcomes are equivalent. However, little work has been conducted to determine if this assumption is supported. The goal of the current study was to determine trial allocation may significantly impact on the psychometric properties of a commonly used self-report postnatal depression screening questionnaire. METHODS: Utilising data from a prospective randomised controlled trial (RCT) investigating the impact of antenatal exercise on psychological well-being, postnatal depression was assessed using the Edinburgh Postnatal Depression Scale (EPDS) at the 12-16 weeks following birth. Structural equation modeling approaches were used to investigate the assumption of measurement invariance of the EPDS using a two-
